Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Enrolling by invitation2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

enrolling_by_invitation267%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationphase_1

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

NCT05577312
enrolling_by_invitationnot_applicable

Clinical Study of BRL-101 in Severe SCD

NCT06300723
not_yet_recruitingnot_applicable

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

NCT06287099

Clinical Trials (3)

Showing 3 of 3 trials
NCT05577312Phase 1

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Enrolling By Invitation
NCT06300723Not Applicable

Clinical Study of BRL-101 in Severe SCD

Enrolling By Invitation
NCT06287099Not Applicable

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3